Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
Lantern Pharma Inc. (LTRN), a clinical-stage biotech firm focused on AI-driven oncology therapeutic development, is trading at a current price of $1.61 as of 2026-04-06, marking a -0.68% change in the most recent trading session. This analysis outlines key technical levels, recent market context, and potential near-term scenarios for LTRN, as the stock has traded in a tight range in recent weeks with limited fundamental catalysts available to investors as of this month. No recent earnings data i
Is Lantern Pharma (LTRN) Stock Worth Buying Now | Price at $1.61, Down 0.68% - Rating Change
LTRN - Stock Analysis
3694 Comments
761 Likes
1
Ramel
Power User
2 hours ago
Indices continue to test intraday highs with moderate volume.
👍 186
Reply
2
Kamor
Loyal User
5 hours ago
Anyone else just stumbled into this?
👍 193
Reply
3
Jayonte
Legendary User
1 day ago
Real-time US stock market capitalization analysis and size classification for appropriate risk assessment and position sizing decisions. We help you understand how company size impacts volatility and expected returns in different market conditions and economic environments. We provide size analysis, volatility by market cap, and size factor returns for comprehensive coverage. Understand size impact with our comprehensive capitalization analysis and size classification tools for risk management.
👍 240
Reply
4
Dearii
New Visitor
1 day ago
This feels like knowledge from the future.
5
Panya
Experienced Member
2 days ago
It’s frustrating to realize this after the fact.
👍 14
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.